Last reviewed · How we verify
NCT05523193: JXVD
Valvular Heart Disease in Jiangxi Province
trial testing Formal treatment model in Valvular Heart Disease in 1,052 participants. Status unknown.
31 August 2023
Quick facts
| Lead sponsor | Xiao Huang |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,052 |
| Start date | 1 August 2022 |
| Primary completion | 31 August 2023 |
| Estimated completion | 31 August 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Formal treatment model
Conditions studied
- Valvular Heart Disease — all drugs for Valvular Heart Disease →
- Treatment Adherence and Compliance — all drugs for Treatment Adherence and Compliance →
Sponsor
Xiao Huang
Who can join
Eligibility, any sex, with Valvular Heart Disease or Treatment Adherence and Compliance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study Title: A real-world study of valvular heart disease in Jiangxi Province Research Objectives: ① Main objectives: To examine the current incidence of valvular heart disease in Jiangxi Province, to establish a "Formal treatment model" for patients with valvular heart disease, and to manage the collection of diagnostic, therapeutic and prognostic data on patients. ② Secondary objective: To investigate the composite of all-cause mortality, disabling stroke, permanent pacemaker implantation, and moderate or greater valve regurgitation in the "Formal treatment model" group and the "Conventional treatment model" group. The Conventional group was matched to patients who were not in the " Formal treatment model " during the same period. Design type: a prospective, observational, real-world study (at least 1.5 years). No pre-established fixed treatment protocols, only a Formal treatment model,with all treatment choices made entirely by clinicians following relevant textbooks, expert consensus on clinical guidelines, and based on the patient's condition. Subjects: All patients with moderate to severe heart valve disease were collected from the Second Affiliated Hospital of Nanchang University and hospitals at all levels in Jiangxi Province from September 2022 to September 2023.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05523193
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Valvular Heart Disease
Currently open trials in the same condition.
- NCT07197736 — DELINEATE-Prospective · recruiting
- NCT07042529 — Optimized Expansion of the Implanted Transcatheter Aortic Valve · NA · recruiting
- NCT07065500 — Mechanism and Effect of Novel Metabolites on Valvular Heart Disease · recruiting
- NCT07099417 — Screening of Valvular Heart Disease Using Single-channel Electrocardiogram · recruiting
- NCT06386016 — Detection of Valvular Heart Disease Using Artificial Intelligence-based Stethoscope · recruiting
Other Xiao Huang trials
Trials by the same sponsor.
- NCT05498909 — A Real-world Registry Study of Multidisciplinary Collaborative Diagnosis and Treatment Model for Cardioembolic Stroke · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05523193 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiao Huang
- Last refreshed: 31 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05523193.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing